Children's Oncology Group's 2013 blueprint for research

Renal tumors

Jeffrey S. Dome*, Conrad V. Fernandez, Elizabeth A. Mullen, John A. Kalapurakal, James I. Geller, Vicki Huff, Eric J. Gratias, David B. Dix, Peter F. Ehrlich, Geetika Khanna, Marcio H. Malogolowkin, James R. Anderson, Arlene Naranjo, Elizabeth J. Perlman

*Corresponding author for this work

Research output: Contribution to journalReview article

64 Citations (Scopus)

Abstract

Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.

Original languageEnglish (US)
Pages (from-to)994-1000
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Wilms Tumor
Kidney
Research
Neoplasms
Histology
Clear Cell Sarcoma
Rhabdoid Tumor
Pediatrics
Biological Therapy
Renal Cell Carcinoma
Chromosomes
Biomarkers
Clinical Trials
Therapeutics

Keywords

  • Clear cell sarcoma
  • Malignant rhabdoid tumor
  • Renal cell carcinoma
  • Wilms tumor

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Dome, Jeffrey S. ; Fernandez, Conrad V. ; Mullen, Elizabeth A. ; Kalapurakal, John A. ; Geller, James I. ; Huff, Vicki ; Gratias, Eric J. ; Dix, David B. ; Ehrlich, Peter F. ; Khanna, Geetika ; Malogolowkin, Marcio H. ; Anderson, James R. ; Naranjo, Arlene ; Perlman, Elizabeth J. / Children's Oncology Group's 2013 blueprint for research : Renal tumors. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 6. pp. 994-1000.
@article{7866bd5e61794e46926d7985d14c4156,
title = "Children's Oncology Group's 2013 blueprint for research: Renal tumors",
abstract = "Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90{\%}. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.",
keywords = "Clear cell sarcoma, Malignant rhabdoid tumor, Renal cell carcinoma, Wilms tumor",
author = "Dome, {Jeffrey S.} and Fernandez, {Conrad V.} and Mullen, {Elizabeth A.} and Kalapurakal, {John A.} and Geller, {James I.} and Vicki Huff and Gratias, {Eric J.} and Dix, {David B.} and Ehrlich, {Peter F.} and Geetika Khanna and Malogolowkin, {Marcio H.} and Anderson, {James R.} and Arlene Naranjo and Perlman, {Elizabeth J.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1002/pbc.24419",
language = "English (US)",
volume = "60",
pages = "994--1000",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

Dome, JS, Fernandez, CV, Mullen, EA, Kalapurakal, JA, Geller, JI, Huff, V, Gratias, EJ, Dix, DB, Ehrlich, PF, Khanna, G, Malogolowkin, MH, Anderson, JR, Naranjo, A & Perlman, EJ 2013, 'Children's Oncology Group's 2013 blueprint for research: Renal tumors', Pediatric Blood and Cancer, vol. 60, no. 6, pp. 994-1000. https://doi.org/10.1002/pbc.24419

Children's Oncology Group's 2013 blueprint for research : Renal tumors. / Dome, Jeffrey S.; Fernandez, Conrad V.; Mullen, Elizabeth A.; Kalapurakal, John A.; Geller, James I.; Huff, Vicki; Gratias, Eric J.; Dix, David B.; Ehrlich, Peter F.; Khanna, Geetika; Malogolowkin, Marcio H.; Anderson, James R.; Naranjo, Arlene; Perlman, Elizabeth J.

In: Pediatric Blood and Cancer, Vol. 60, No. 6, 01.06.2013, p. 994-1000.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Children's Oncology Group's 2013 blueprint for research

T2 - Renal tumors

AU - Dome, Jeffrey S.

AU - Fernandez, Conrad V.

AU - Mullen, Elizabeth A.

AU - Kalapurakal, John A.

AU - Geller, James I.

AU - Huff, Vicki

AU - Gratias, Eric J.

AU - Dix, David B.

AU - Ehrlich, Peter F.

AU - Khanna, Geetika

AU - Malogolowkin, Marcio H.

AU - Anderson, James R.

AU - Naranjo, Arlene

AU - Perlman, Elizabeth J.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.

AB - Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.

KW - Clear cell sarcoma

KW - Malignant rhabdoid tumor

KW - Renal cell carcinoma

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=84876430490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876430490&partnerID=8YFLogxK

U2 - 10.1002/pbc.24419

DO - 10.1002/pbc.24419

M3 - Review article

VL - 60

SP - 994

EP - 1000

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -